Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. develops clinical-stage cancer therapeutics focused on multi-node inhibition of oncogenic pathways. Its lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to target PI3K-alpha and dual mTORC1/2 nodes in the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company also reports on solnerstotug, a V-domain Ig suppressor of T cell activation, or VISTA, inhibitor for advanced solid tumors.
Recurring company news includes oncology trial activity, clinical and regulatory disclosures, operating and financial results, governance updates, capital-structure matters, and Nasdaq inducement equity grants tied to employee compensation.
Sensei Biotherapeutics, Inc. reported financial results for Q1 2024 and recent business highlights, including clinical trial progress, upcoming data presentations, and a strong balance sheet with cash runway into Q4 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.